Newsroom

High Cost Drugs Threaten the Sustainability of Medicare

This is an important time to think about the future of programs and policies that support us as we age. Medicare marks its 50th Anniversary at the end of July. I’ve been around to witness much of the creation and evolution of health policy. After a 40-year career in Aging and Health Policy, first in the Senate, then at AARP, and now as head of the National Coalition on Health Care, I have a few observations about where things stand.

Read more

PRESS STATEMENT: National Health Expenditure Projections Show Sharp Rise in Rx Spending

“These numbers paint a troubling picture for the future of the American economy. The dramatic rise in prescription drug spending proves that it is more important than ever to advance a solution to monopolistic drug pricing. We cannot afford to continue on this unsustainable path.”

Read more

The Hill: FDA approves cholesterol drug with $15,000 yearly price tag

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but its price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years,” John Rother, president of the National Coalition on Health Care, said in a statement.

Read more

PRESS STATEMENT: FDA Approves Praluent, New Cholesterol-Lowering Treatment

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but it’s price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years.”

Read more